Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018
Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hyperten...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Wilkens, Heinrike [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Umfang: |
10 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet - Fabersani, Emanuel ELSEVIER, 2018, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:272 ; year:2018 ; day:1 ; month:12 ; pages:69-78 ; extent:10 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijcard.2018.08.079 |
|---|
| Katalog-ID: |
ELV045335346 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045335346 | ||
| 003 | DE-627 | ||
| 005 | 20230626011136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190205s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2018.08.079 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000473.pica |
| 035 | |a (DE-627)ELV045335346 | ||
| 035 | |a (ELSEVIER)S0167-5273(18)34354-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 630 |a 640 |a 610 |q VZ |
| 100 | 1 | |a Wilkens, Heinrike |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 10 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. | ||
| 520 | |a Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. | ||
| 700 | 1 | |a Konstantinides, Stavros |4 oth | |
| 700 | 1 | |a Lang, Irene M. |4 oth | |
| 700 | 1 | |a Bunck, Alexander C. |4 oth | |
| 700 | 1 | |a Gerges, Mario |4 oth | |
| 700 | 1 | |a Gerhardt, Felix |4 oth | |
| 700 | 1 | |a Grgic, Aleksandar |4 oth | |
| 700 | 1 | |a Grohé, Christian |4 oth | |
| 700 | 1 | |a Guth, Stefan |4 oth | |
| 700 | 1 | |a Held, Matthias |4 oth | |
| 700 | 1 | |a Hinrichs, Jan B. |4 oth | |
| 700 | 1 | |a Hoeper, Marius M. |4 oth | |
| 700 | 1 | |a Klepetko, Walter |4 oth | |
| 700 | 1 | |a Kramm, Thorsten |4 oth | |
| 700 | 1 | |a Krüger, Ulrich |4 oth | |
| 700 | 1 | |a Lankeit, Mareike |4 oth | |
| 700 | 1 | |a Meyer, Bernhard C. |4 oth | |
| 700 | 1 | |a Olsson, Karen M. |4 oth | |
| 700 | 1 | |a Schäfers, Hans-Joachim |4 oth | |
| 700 | 1 | |a Schmidt, Matthias |4 oth | |
| 700 | 1 | |a Seyfarth, Hans-J |4 oth | |
| 700 | 1 | |a Ulrich, Silvia |4 oth | |
| 700 | 1 | |a Wiedenroth, Christoph B. |4 oth | |
| 700 | 1 | |a Mayer, Eckhard |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Fabersani, Emanuel ELSEVIER |t Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |d 2018 |g Amsterdam [u.a.] |w (DE-627)ELV000849189 |
| 773 | 1 | 8 | |g volume:272 |g year:2018 |g day:1 |g month:12 |g pages:69-78 |g extent:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijcard.2018.08.079 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 272 |j 2018 |b 1 |c 1201 |h 69-78 |g 10 | ||
| author_variant |
h w hw |
|---|---|
| matchkey_str |
wilkensheinrikekonstantinidesstavroslang:2018----:hoitrmomoiploayyetnintpudtdeomnainfoteo |
| hierarchy_sort_str |
2018transfer abstract |
| publishDate |
2018 |
| allfields |
10.1016/j.ijcard.2018.08.079 doi GBV00000000000473.pica (DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 DE-627 ger DE-627 rakwb eng 630 640 610 VZ Wilkens, Heinrike verfasserin aut Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Konstantinides, Stavros oth Lang, Irene M. oth Bunck, Alexander C. oth Gerges, Mario oth Gerhardt, Felix oth Grgic, Aleksandar oth Grohé, Christian oth Guth, Stefan oth Held, Matthias oth Hinrichs, Jan B. oth Hoeper, Marius M. oth Klepetko, Walter oth Kramm, Thorsten oth Krüger, Ulrich oth Lankeit, Mareike oth Meyer, Bernhard C. oth Olsson, Karen M. oth Schäfers, Hans-Joachim oth Schmidt, Matthias oth Seyfarth, Hans-J oth Ulrich, Silvia oth Wiedenroth, Christoph B. oth Mayer, Eckhard oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 https://doi.org/10.1016/j.ijcard.2018.08.079 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 272 2018 1 1201 69-78 10 |
| spelling |
10.1016/j.ijcard.2018.08.079 doi GBV00000000000473.pica (DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 DE-627 ger DE-627 rakwb eng 630 640 610 VZ Wilkens, Heinrike verfasserin aut Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Konstantinides, Stavros oth Lang, Irene M. oth Bunck, Alexander C. oth Gerges, Mario oth Gerhardt, Felix oth Grgic, Aleksandar oth Grohé, Christian oth Guth, Stefan oth Held, Matthias oth Hinrichs, Jan B. oth Hoeper, Marius M. oth Klepetko, Walter oth Kramm, Thorsten oth Krüger, Ulrich oth Lankeit, Mareike oth Meyer, Bernhard C. oth Olsson, Karen M. oth Schäfers, Hans-Joachim oth Schmidt, Matthias oth Seyfarth, Hans-J oth Ulrich, Silvia oth Wiedenroth, Christoph B. oth Mayer, Eckhard oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 https://doi.org/10.1016/j.ijcard.2018.08.079 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 272 2018 1 1201 69-78 10 |
| allfields_unstemmed |
10.1016/j.ijcard.2018.08.079 doi GBV00000000000473.pica (DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 DE-627 ger DE-627 rakwb eng 630 640 610 VZ Wilkens, Heinrike verfasserin aut Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Konstantinides, Stavros oth Lang, Irene M. oth Bunck, Alexander C. oth Gerges, Mario oth Gerhardt, Felix oth Grgic, Aleksandar oth Grohé, Christian oth Guth, Stefan oth Held, Matthias oth Hinrichs, Jan B. oth Hoeper, Marius M. oth Klepetko, Walter oth Kramm, Thorsten oth Krüger, Ulrich oth Lankeit, Mareike oth Meyer, Bernhard C. oth Olsson, Karen M. oth Schäfers, Hans-Joachim oth Schmidt, Matthias oth Seyfarth, Hans-J oth Ulrich, Silvia oth Wiedenroth, Christoph B. oth Mayer, Eckhard oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 https://doi.org/10.1016/j.ijcard.2018.08.079 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 272 2018 1 1201 69-78 10 |
| allfieldsGer |
10.1016/j.ijcard.2018.08.079 doi GBV00000000000473.pica (DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 DE-627 ger DE-627 rakwb eng 630 640 610 VZ Wilkens, Heinrike verfasserin aut Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Konstantinides, Stavros oth Lang, Irene M. oth Bunck, Alexander C. oth Gerges, Mario oth Gerhardt, Felix oth Grgic, Aleksandar oth Grohé, Christian oth Guth, Stefan oth Held, Matthias oth Hinrichs, Jan B. oth Hoeper, Marius M. oth Klepetko, Walter oth Kramm, Thorsten oth Krüger, Ulrich oth Lankeit, Mareike oth Meyer, Bernhard C. oth Olsson, Karen M. oth Schäfers, Hans-Joachim oth Schmidt, Matthias oth Seyfarth, Hans-J oth Ulrich, Silvia oth Wiedenroth, Christoph B. oth Mayer, Eckhard oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 https://doi.org/10.1016/j.ijcard.2018.08.079 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 272 2018 1 1201 69-78 10 |
| allfieldsSound |
10.1016/j.ijcard.2018.08.079 doi GBV00000000000473.pica (DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 DE-627 ger DE-627 rakwb eng 630 640 610 VZ Wilkens, Heinrike verfasserin aut Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 2018transfer abstract 10 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. Konstantinides, Stavros oth Lang, Irene M. oth Bunck, Alexander C. oth Gerges, Mario oth Gerhardt, Felix oth Grgic, Aleksandar oth Grohé, Christian oth Guth, Stefan oth Held, Matthias oth Hinrichs, Jan B. oth Hoeper, Marius M. oth Klepetko, Walter oth Kramm, Thorsten oth Krüger, Ulrich oth Lankeit, Mareike oth Meyer, Bernhard C. oth Olsson, Karen M. oth Schäfers, Hans-Joachim oth Schmidt, Matthias oth Seyfarth, Hans-J oth Ulrich, Silvia oth Wiedenroth, Christoph B. oth Mayer, Eckhard oth Enthalten in Elsevier Science Fabersani, Emanuel ELSEVIER Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet 2018 Amsterdam [u.a.] (DE-627)ELV000849189 volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 https://doi.org/10.1016/j.ijcard.2018.08.079 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 272 2018 1 1201 69-78 10 |
| language |
English |
| source |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 |
| sourceStr |
Enthalten in Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet Amsterdam [u.a.] volume:272 year:2018 day:1 month:12 pages:69-78 extent:10 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| dewey-raw |
630 |
| isfreeaccess_bool |
false |
| container_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| authorswithroles_txt_mv |
Wilkens, Heinrike @@aut@@ Konstantinides, Stavros @@oth@@ Lang, Irene M. @@oth@@ Bunck, Alexander C. @@oth@@ Gerges, Mario @@oth@@ Gerhardt, Felix @@oth@@ Grgic, Aleksandar @@oth@@ Grohé, Christian @@oth@@ Guth, Stefan @@oth@@ Held, Matthias @@oth@@ Hinrichs, Jan B. @@oth@@ Hoeper, Marius M. @@oth@@ Klepetko, Walter @@oth@@ Kramm, Thorsten @@oth@@ Krüger, Ulrich @@oth@@ Lankeit, Mareike @@oth@@ Meyer, Bernhard C. @@oth@@ Olsson, Karen M. @@oth@@ Schäfers, Hans-Joachim @@oth@@ Schmidt, Matthias @@oth@@ Seyfarth, Hans-J @@oth@@ Ulrich, Silvia @@oth@@ Wiedenroth, Christoph B. @@oth@@ Mayer, Eckhard @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000849189 |
| dewey-sort |
3630 |
| id |
ELV045335346 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045335346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626011136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2018.08.079</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000473.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045335346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(18)34354-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wilkens, Heinrike</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Konstantinides, Stavros</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lang, Irene M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bunck, Alexander C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerges, Mario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerhardt, Felix</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grgic, Aleksandar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grohé, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guth, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Held, Matthias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hinrichs, Jan B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoeper, Marius M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klepetko, Walter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kramm, Thorsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krüger, Ulrich</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lankeit, Mareike</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyer, Bernhard C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olsson, Karen M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schäfers, Hans-Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, Matthias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seyfarth, Hans-J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ulrich, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wiedenroth, Christoph B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mayer, Eckhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:272</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:69-78</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2018.08.079</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">272</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">1201</subfield><subfield code="h">69-78</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| author |
Wilkens, Heinrike |
| spellingShingle |
Wilkens, Heinrike ddc 630 Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| authorStr |
Wilkens, Heinrike |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000849189 |
| format |
electronic Article |
| dewey-ones |
630 - Agriculture & related technologies 640 - Home & family management 610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
630 640 610 VZ Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| topic |
ddc 630 |
| topic_unstemmed |
ddc 630 |
| topic_browse |
ddc 630 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
s k sk i m l im iml a c b ac acb m g mg f g fg a g ag c g cg s g sg m h mh j b h jb jbh m m h mm mmh w k wk t k tk u k uk m l ml b c m bc bcm k m o km kmo h j s hjs m s ms h j s hjs s u su c b w cb cbw e m em |
| hierarchy_parent_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| hierarchy_parent_id |
ELV000849189 |
| dewey-tens |
630 - Agriculture 640 - Home & family management 610 - Medicine & health |
| hierarchy_top_title |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000849189 |
| title |
Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| ctrlnum |
(DE-627)ELV045335346 (ELSEVIER)S0167-5273(18)34354-7 |
| title_full |
Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| author_sort |
Wilkens, Heinrike |
| journal |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| journalStr |
Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
69 |
| author_browse |
Wilkens, Heinrike |
| container_volume |
272 |
| physical |
10 |
| class |
630 640 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Wilkens, Heinrike |
| doi_str_mv |
10.1016/j.ijcard.2018.08.079 |
| dewey-full |
630 640 610 |
| title_sort |
chronic thromboembolic pulmonary hypertension (cteph): updated recommendations from the cologne consensus conference 2018 |
| title_auth |
Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| abstract |
Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. |
| abstractGer |
Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. |
| abstract_unstemmed |
Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018 |
| url |
https://doi.org/10.1016/j.ijcard.2018.08.079 |
| remote_bool |
true |
| author2 |
Konstantinides, Stavros Lang, Irene M. Bunck, Alexander C. Gerges, Mario Gerhardt, Felix Grgic, Aleksandar Grohé, Christian Guth, Stefan Held, Matthias Hinrichs, Jan B. Hoeper, Marius M. Klepetko, Walter Kramm, Thorsten Krüger, Ulrich Lankeit, Mareike Meyer, Bernhard C. Olsson, Karen M. Schäfers, Hans-Joachim Schmidt, Matthias Seyfarth, Hans-J Ulrich, Silvia Wiedenroth, Christoph B. Mayer, Eckhard |
| author2Str |
Konstantinides, Stavros Lang, Irene M. Bunck, Alexander C. Gerges, Mario Gerhardt, Felix Grgic, Aleksandar Grohé, Christian Guth, Stefan Held, Matthias Hinrichs, Jan B. Hoeper, Marius M. Klepetko, Walter Kramm, Thorsten Krüger, Ulrich Lankeit, Mareike Meyer, Bernhard C. Olsson, Karen M. Schäfers, Hans-Joachim Schmidt, Matthias Seyfarth, Hans-J Ulrich, Silvia Wiedenroth, Christoph B. Mayer, Eckhard |
| ppnlink |
ELV000849189 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ijcard.2018.08.079 |
| up_date |
2024-07-06T17:14:32.624Z |
| _version_ |
1803850688890929152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045335346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626011136.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijcard.2018.08.079</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000473.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045335346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-5273(18)34354-7</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="a">640</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wilkens, Heinrike</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">10</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Chronic thromboembolic pulmonary hypertension (CTEPH) is a subgroup of pulmonary hypertension that differs from all other forms of PH in terms of its pathophysiology, patient characteristics and treatment. For implementation of the European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension in Germany, the Cologne Consensus Conference 2016 was held and last updated in spring of 2018. One of the working groups was dedicated to CTEPH, practical and controversial issues were commented and updated. In every patient with suspected PH, CTEPH or chronic thromboembolic disease (CTED, i.e. symptomatic residual vasculopathy without pulmonary hypertension) should be excluded. Primary treatment is surgical pulmonary endarterectomy (PEA) in a multidisciplinary CTEPH centre. Inoperable patients or patients with persistent or recurrent CTEPH after PEA are candidates for targeted drug therapy. There is increasing experience with balloon pulmonary angioplasty (BPA) for inoperable patients; this option, like PEA, is reserved for specialised centres with expertise in this treatment method.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Konstantinides, Stavros</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lang, Irene M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bunck, Alexander C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerges, Mario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gerhardt, Felix</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grgic, Aleksandar</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grohé, Christian</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guth, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Held, Matthias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hinrichs, Jan B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoeper, Marius M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klepetko, Walter</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kramm, Thorsten</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Krüger, Ulrich</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lankeit, Mareike</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Meyer, Bernhard C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olsson, Karen M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schäfers, Hans-Joachim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmidt, Matthias</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seyfarth, Hans-J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ulrich, Silvia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wiedenroth, Christoph B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mayer, Eckhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Fabersani, Emanuel ELSEVIER</subfield><subfield code="t">Metabolic effects of goat milk yogurt supplemented with yacon flour in rats on high-fat diet</subfield><subfield code="d">2018</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV000849189</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:272</subfield><subfield code="g">year:2018</subfield><subfield code="g">day:1</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:69-78</subfield><subfield code="g">extent:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijcard.2018.08.079</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">272</subfield><subfield code="j">2018</subfield><subfield code="b">1</subfield><subfield code="c">1201</subfield><subfield code="h">69-78</subfield><subfield code="g">10</subfield></datafield></record></collection>
|
| score |
7.4004354 |